Innovative drugs approved via priority review pathway
Number of innovative drugs approved for marketing through expedited priority review procedures.
Unit Count Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Innovative drugs approved via priority review pathway
China, 2024
Every record
All records
2 records · 1 region · 2024
| Period | Value | Source | Type |
|---|---|---|---|
| China 2 records | |||
| 2024 | 17 | State Council · 31 Dec 2024 | actual |
| 2024 | 17 | NMPA · 31 Dec 2024 | actual |
Primary documents
Sources
2 documents. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Measures facilitate approval of 48 first-in-class innovative drugs | NMPA | — | 1 |
| Measures facilitate approval of 48 first-in-class innovative drugs | State Council | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Innovative drugs approved via priority review pathway. Retrieved from https://statorigin.org/indicators/innovative-drugs-approved-via-priority-review-pathway